Finland has built a clinical research ecosystem around something few countries can reproduce: deeply connected genomic, biobank and longitudinal health data.
With a population of 5.6 million and more than 2,500 trials listed on ClinicalTrials.gov, Finland already has meaningful clinical research scale. Its real differentiation, however, comes from the infrastructure behind those trials.
FinnGen brings together genetic and health data from more than 500,000 Finnish biobank participants and works with major global pharmaceutical companies. This creates a powerful environment for target discovery, patient stratification, biomarker research and genotype phenotype analysis.
Finland’s five university hospitals provide national academic coverage, while the Finnish Biobank Cooperative connects 13 regional biobanks through a harmonised access framework. Sponsors can therefore approach biosample and data driven research through a much more coordinated national ecosystem.
The country also has exceptional research depth across Type 1 diabetes, rare genetic conditions, oncology, cardiovascular medicine, neuroscience and metabolic research.
For sponsors, the practical value is clear. Finland can connect specialist investigators, longitudinal electronic health information, biobank samples and genomic data within the same research environment, making it particularly relevant for precision medicine programs and trials requiring deeper biological characterisation of patient populations.
